Details

Autor(en) / Beteiligte

• Garrido, David
• Slavutsky, Irma
• Riva, Eloisa
• Peña, Camila
• Schutz, Natalia
• Tarín-Arzaga, Luz
• Martínez-Cordero, Humberto
• Bove, Virginia
• Osorio, Rocío
• Chandía, Mauricio
• Beltrán, Cecilia
• Schulz, Javier
• Cardemil, Daniela
• Contreras, Carolina
• Vergara, Carmen Gloria
• Donoso, Javiera
• Espinoza, Marcela
• La Rocca, Gabriel
• López-Vidal, Hernán
• León, Pilar
• Hopkins, Christine Rojas
• Soto, Pablo
• Aranda, Sandra
• Torres, Vivianne
• Roa, Macarena
• Ochoa, Paola
• Duarte, Patricio Jose
• Remaggi, Guillermina
• Yantorno, Sebastián
• Corzo, Ariel
• Zabaljauregui, Soledad
• Shanley, Claudia
• Lopresti, Sergio
• Orlando, Sergio
• Verri, Verónica
• Quiroga, Luis
• García, Carlos
• Fernández, Vanesa
• Ramirez, Jhoanna
• Verduga, Azucena
• Molina, Alicia
• Pacheco, María
• Mantilla, William
• Mite, Alex
• Reyes, Inés
• Sabando, Brenner
• Ramírez, Francisca
• Sossa, Claudia
• Abello, Virginia
• Idrobo, Henry
• Cardenas, Kenny Mauricio Galvez
• Saavedra, Domingo
• Quintero, Guillermo
• Gazitúa, Raimundo
• Gaviria, Lina
• Gomez, Rigoberto
• Osuna, Mónica
• Henao-Uribe, Alicia
• Cantú-Martínez, Omar
• Gómez-Almaguer, David
• García-Navarrete, Yarely Itzayana
• Cruz-Mora, Antonio
• Cantero-Fortiz, Yahveth
• Ruiz-Argüelles, Guillermo J
• Fantl, Dorotea

Titel

Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting

Ist Teil von

• Current problems in cancer, 2023-02, Vol.47 (1), p.100916-100916, Article 100916

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Quelle

ScienceDirect

Beschreibungen/Notizen

• Cytogenetic abnormalities (CA) such as t(4;14), t(14;16), and del(17p), are associated with a poor prognosis in Multiple Myeloma (MM) patients. However, there is scarce information regarding the Latin-American population. This study aims to analyze the impact of t(4;14), t(14;16), and del(17p) on the progression-free survival (PFS) and overall survival (OS) of transplant-eligible newly-diagnosed MM (NDMM) patients in Latin America. Retrospective survival analysis based on the Grupo de Estudio Latinoamericano de MM (GELAMM) registry, including all adult patients with NDMM harboring CA t(4;14), t(14;16), and/or del(17p). Fifty-nine patients were included; the median age was 57 years, 55.9% males, 22% ISS-I, 25.4% ISS-II, and 47.5% ISS-III. The majority (89.8%) had one alteration, whereas 10.2% had del(17p) and t(4;14). The frequencies of CA were del(17p) in 61.0%, t(4;14) in 25.4%, and t(14;16) in 3,4%. Autologous stem cell transplantation was performed in 36 cases, 20 patients did not use this consolidative strategy, and this data was missed in three cases. Five-year OS for the entire cohort was 60.8% and 5-year PFS was 28.1%. Bortezomib-based induction regimen (BBR) (p=0.029), consolidation with ASCT (p<0.001), and maintenance therapy (p=0.004) were associated with an improved 5-year OS. In the multivariate analysis, ASCT was the only variable with a positive impact on OS (HR 0.11, 95% CI 0.033 to 0.34, p<0.001). The median PFS presented a non-statistically significant benefit in BBR, ASCT, and maintenance therapy groups. BBR induction, ASCT, and maintenance therapy were associated with improved OS in high-risk NDMM patients.